Abstract | OBJECTIVE: The primary objective of this review is to examine which disease-modifying antirheumatic drugs (DMARDs) and biologics used to treat pregnant individuals with rheumatic conditions have been reported in observational studies using population-based health administrative data. The secondary objective is to describe which adverse pregnancy outcomes (both maternal and neonatal) have been reported, their definitions, and corresponding diagnostic and/or procedural codes. INTRODUCTION: Pregnant individuals are typically excluded from drug trials due to unknown potential risks to both mother and fetus, leaving most antirheumatic drugs understudied for use in pregnancy. Despite these substantial knowledge gaps, most pregnant individuals continue to be maintained on antirheumatic medications due to benefits generally outweighing risks. In contrast to previous systematic reviews of findings from randomized trials, our scoping review aims to leverage this real-world data to generate real-world evidence on antirheumatic drug safety during pregnancy. INCLUSION CRITERIA: METHODS: Electronic databases (MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCOhost)) and gray literature (OpenGrey, Health Services Research Projects in Progress, World Health Organization Library, and Google Scholar) will be searched for relevant evidence. Search terms will combine 4 concepts: rheumatic diseases, drug therapy, pregnancy, and health care administrative data. Identified articles will be independently screened, selected, and extracted by 2 researchers. Data will be analyzed descriptively and presented in tables. DETAILS OF THIS REVIEW ARE AVAILABLE AT OPEN SCIENCE FRAMEWORK: https://osf.io/5e6tp.
|
Authors | Shenthuraan Tharmarajah, Sara Guilcher, Araniy Santhireswaran, Lisa McCarthy, Dharini Mahendira, Howard Berger, Mina Tadrous |
Journal | JBI evidence synthesis
(JBI Evid Synth)
(Sep 22 2023)
ISSN: 2689-8381 [Electronic] United States |
PMID | 37732935
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 JBI. |